Ginkgo Bioworks Holdings, Inc. — Form 8-K Summary
Business Context and Reporting Period
Filed August 23, 2023, under Items 8.01 and 9.01. The filing updates pro forma financial information related to Ginkgo’s acquisition of Zymergen Inc., completed October 19, 2022. It includes an unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022.
Financial Information
The filing identifies Exhibit 99.1 as the source of the updated pro forma statement of operations. The provided filing text does not include the statement’s numerical amounts; therefore, revenue, profit or loss, cash flow, margins, debt, liquidity, and other financial metrics cannot be determined from the text provided.
Material Changes Versus Prior Period
This filing further updates certain pro forma financial information previously reported in Ginkgo’s January 27, 2023 Form 8-K. The filing text does not describe the specific adjustments or quantify changes versus the previously reported information.
Guidance, Outlook, Risks, and Unusual Items
No management guidance, outlook, risk discussion, contingencies, or operating commentary is provided. The principal unusual item is the pro forma presentation reflecting the Zymergen acquisition; pro forma results are not necessarily indicative of results that would have occurred had the acquisition taken place earlier or of future results.
Investor Verification Points
- Review Exhibit 99.1 for the actual pro forma revenue, expenses, operating results, and net income or loss for the year ended December 31, 2022.
- Compare Exhibit 99.1 with the pro forma information filed on January 27, 2023 to identify the updated adjustments.
- Confirm the assumptions and purchase-accounting adjustments used to combine Ginkgo and Zymergen.
- Distinguish the pro forma statement from Ginkgo’s reported historical results and current financial outlook.